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ABSTRACT
Introduction: An increasing number of people are
living with multimorbidity. The evidence base for how
best to manage these patients is weak. Current clinical
guidelines generally focus on single conditions, which
may not reflect the needs of patients with
multimorbidity. The aim of the 3D study is to develop,
implement and evaluate an intervention to improve the
management of patients with multimorbidity in general
practice.
Methods and analysis: This is a pragmatic two-arm
cluster randomised controlled trial. 32 general practices
around Bristol, Greater Manchester and Glasgow will be
randomised to receive either the ‘3D intervention’ or
usual care. 3D is a complex intervention including
components affecting practice organisation, the conduct
of patient reviews, integration with secondary care and
measures to promote change in practice organisation.
Changes include improving continuity of care and
replacing reviews of each disease with patient-centred
reviews with a focus on patients’ quality of life, mental
health and polypharmacy. We aim to recruit 1383
patients who have 3 or more chronic conditions. This
provides 90% power at 5% significance level to detect
an effect size of 0.27 SDs in the primary outcome,
which is health-related quality of life at 15 months using
the EQ-5D-5L. Secondary outcome measures assess
patient centredness, illness burden and treatment
burden. The primary analysis will be a multilevel
regression model adjusted for baseline, stratification/
minimisation, clustering and important co-variables.
Nested process evaluation will assess implementation,
mechanisms of effectiveness and interaction of the
intervention with local context. Economic analysis of
cost-consequences and cost-effectiveness will be based
on quality-adjusted life years.
Ethics and dissemination: This study has approval
from South-West (Frenchay) National Health Service
(NHS) Research Ethics Committee (14/SW/0011).
Findings will be disseminated via final report, peer-
reviewed publications and guidance to healthcare
professionals, commissioners and policymakers.
Trial registration number: ISRCTN06180958; Pre-
results.
INTRODUCTION
An increasing number of people are living
with multiple chronic conditions or multi-
morbidity. At least 16% of adult patients in
primary care in the UK have multimorbidity
and prevalence increases with age.1 2 These
patients experience a high level of ‘illness
burden’ due to poor quality of life, high
rates of depression (which often goes unrec-
ognised) and reduced life expectancy.2 3
They also experience ‘treatment burden’
due to having to attend multiple specialist
clinics and seeing many different profes-
sionals, which can be inconvenient for
Strengths and limitations of this study
▪ This large trial design draws on considerable evi-
dence about problems experienced by patients
with multimorbidity and is based on an
evidence-based conceptual framework for how
best to improve their management in general
practice.
▪ The healthcare landscape is constantly changing
and ‘usual care’ is variable; therefore, a nested
process evaluation will explore how, why and in
what contexts the intervention is or is not
effective.
▪ This study is limited by its focus on how the UK
National Health Service organises general prac-
tice in England and Scotland. The findings may
not all be generalisable to countries which have
different types of healthcare system.
▪ Given the lack of a universally agreed definition
of multimorbidity, we have defined our multimor-
bidity study population based on having three or
more conditions included in the UK Quality and
Outcomes Framework. Although this will include
participants with a wide range of disease combi-
nations, different definitions of multimorbidity
would lead to inclusion of patients with different
characteristics.
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patients as well as inefficient for the health service.4–6
They may have to take multiple medications in complex
regimes.7 This polypharmacy can be burdensome for
patients, increases the likelihood of interactions and
adverse effects (including those causing hospital admis-
sions), and may reduce medication adherence.8–11
In qualitative studies, patients with multimorbidity
describe a lack of holistic patient-centred care, and a
concern that no single professional takes overall respon-
sibility for their treatment and treats them as a whole
person.4 5 Current treatment guidelines and professional
incentive schemes tend to be focused on individual dis-
eases, which can lead clinicians to focus on disease-
based metrics rather than on the problems that are of
most concern to the individual with multimorbidity.12
Many different sets of guidelines can be relevant to one
patient with multimorbidity, and attempting to follow all
of these guidelines may be excessively burdensome, inef-
ficient and ineffective.7
Multimorbidity represents a challenge to healthcare
systems as well as to individual patients. Patients with
multimorbidity have high rates of primary care consulta-
tions and hospital admissions and they account for a dis-
proportionate amount of overall health service
expenditure.13 In the USA, it is estimated that 75% of
the healthcare expenditure is spent on treating chronic
conditions, while in Europe, the aggregated healthcare
cost multiplies with each additional condition (mean
cost estimate for three conditions=€1631 compared with
€562 for zero conditions).13 From the healthcare profes-
sional’s point of view, patients with multimorbidity can
be challenging to manage.14 15 Clinicians express frustra-
tion with the lack of time, fragmentation of the health-
care system and inadequate guidelines which limit the
care they can offer these patients.16 Complex medication
management is also cited as a particular issue in multi-
morbidity.14–16
The majority of healthcare for people with chronic
conditions is provided in primary care, and therefore
this should be the main setting for approaches to
improve the management of multimorbidity. A recent
Cochrane review highlighted the paucity of research on
interventions to improve the outcomes of patients with
multimorbidity in primary care.17 Ten studies were iden-
tified examining a range of complex interventions which
demonstrated mixed effects. The most effective were
organisational interventions focused on areas of concern
for patients or where they have difficulties, such as func-
tional ability and medication management. No studies
included an economic analysis of cost-effectiveness,
although a trend towards improved prescribing and
medication adherence suggests the potential for cost-
savings. The authors of the systematic review called for
further pragmatic studies based in primary care settings,
using clear definitions of participants and appropriate
outcomes.
In summary, patients with multimorbidity experience
problems of illness burden (poor quality of life,
depression), treatment burden (multiple uncoordinated
appointments, polypharmacy) and lack of person-
centred care (low continuity, little attention paid to
patients’ priorities). This research is designed to test the
hypothesis that a patient-centred intervention in general
practice designed to address the needs and priorities of
patients with multimorbidity will improve their
health-related quality of life, reduce their burden of
illness and treatment and improve their experience of
care, while being more cost-effective than conventional
service models. This will be examined using a cluster
randomised controlled trial (RCT), with economic
evaluation and mixed-methods process evaluation.
METHODS AND ANALYSIS
Trial design
This is a multicentre pragmatic, two-arm, practice-level
cluster RCT (see figure 1), with parallel mixed-methods
process evaluation and economic analysis of cost-
effectiveness. The design is based on the Medical
Research Council (MRC) framework for the evaluation
of complex interventions.18
Conceptual framework
The underlying theoretical basis for the intervention is
the patient-centred care model.19–21 This includes four
key components, all of which are highly relevant to
improving care for patients with multimorbidity:
▸ A focus on the patient’s individual disease and illness
experience: exploring the main reasons for their visit,
their concerns and need for information.
▸ A biopsychosocial perspective: seeking an integrated
understanding of the whole person, including their
emotional needs and life issues.
▸ Finding common ground on what the problem is and
mutually agreeing management plans.
▸ Enhancing the continuing relationship between the
patient and doctor (the therapeutic alliance).
The intervention design is based on a conceptual
framework which delineates the main problems experi-
enced by patients with multimorbidity (drawing on the
existing research evidence) and uses strategies based on
the patient-centred care model to seek to address these
problems. The general approach has many commonal-
ities with well-recognised frameworks such as the
chronic care model22 and the House of Care.23
Participants and setting
This study is based in general practices serving different
patient populations in three geographical areas; in and
around Bristol, Greater Manchester and Glasgow.
Practices in this study will be selected from areas with a
range of socioeconomic characteristics, particularly
levels of deprivation.
In the UK, each patient is registered with one general
practice, typically with between 2 and 10 general practi-
tioners (GPs) and a smaller number of practice nurses.
2 Man M-S, et al. BMJ Open 2016;6:e011261. doi:10.1136/bmjopen-2016-011261
Open Access
copyright.
 o
n
 January 27, 2020 at University of East Anglia. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2016-011261 on 25 April 2016. Downloaded from 
Patients receive almost all of their primary medical care
from their general practice, which acts as gatekeeper to
secondary care services. Patients with multimorbidity are
called in for regular review of each of their medical con-
ditions, often having separate reviews for each condition.
Many reviews are conducted by nurses who use disease-
specific computerised templates to collect relevant data
according to clinical guidelines.
Inclusion and exclusion criteria
General practices
To be eligible for inclusion practices need a minimum
of three GP partners, a minimum list of 4500 registered
patients and to use EMIS Web or EMIS PCS as their
computer system. EMIS is the most common clinical
records system in UK general practice.
Patients
Inclusion criteria are being aged 18 years or over, being
registered with a usual doctor who is participating in the
research study and having three of more chronic condi-
tions from those included in the National Health
Service (NHS) Quality and Outcomes Framework24
(QOF, V.31.0)—see box 1.
Exclusion criteria are: having a life expectancy of less
than 12 months; serious suicidal risk; known to be
leaving the practice within 12 months; unable to
complete questionnaires in English even with the help
of carers; actively taking part in other research involving
extra visits to primary care or other health services;
lacking capacity to consent (as coded in their practice
records, or determined by their GPs, in Scotland only);
being considered unsuitable for the research study by
their GP (eg, recently bereaved or currently
hospitalised).
Carers
Formal or informal carers of patients consenting to take
part in the study will also be invited to contribute by
completing a carer’s questionnaire. Not all patients may
have carers and not all carers may want to take part;
therefore, this constitutes a small and separate substudy
population.
Recruitment of practices
General practices which are potentially interested in
taking part in the trial will be identified with help from
the NHS Clinical Research Networks in England and the
Scottish Primary Care Network. These nationwide net-
works facilitate clinical research by identifying and
recruiting general practices and providing resources to
help practices do research. Local researchers will meet
with key stakeholders at the practice (practice manager,
GPs, practice nurses) in order to explain the study and
its requirement of a commitment to organisational and
procedural change. The practice manager or lead GP
will sign a practice-level consent agreement.
Recruitment of patients
Each participating practice will be asked to search their
practice database using a standard electronic search pro-
vided by the research team to identify potentially eligible
patients who have three or more chronic conditions as
Figure 1 Flow chart of practice and patient recruitment,
implementation and follow-up. GP, general practitioner.
Box 1 Chronic conditions for inclusion
Included patients have three or more diagnoses from the follow-
ing groups of chronic conditions:
▸ Cardiovascular disease or chronic kidney disease (including
coronary heart disease, hypertension, heart failure, peripheral
arterial disease, chronic kidney disease stage 3–5)*
▸ Stroke
▸ Diabetes
▸ Chronic obstructive pulmonary disease or asthma*
▸ Epilepsy
▸ Atrial fibrillation
▸ Severe mental health problems (schizophrenia or psychotic
illness)*
▸ Depression
▸ Dementia
▸ Learning disability
▸ Rheumatoid arthritis
*Groups are counted only once even if a patient has multiple
conditions within a group. For example, having both hypertension
and heart failure would just count for one condition.
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defined by the inclusion criteria. In some practices, not
all GPs will participate, so in practices which have a
policy for patients to see the same GP, only those
patients who usually see one of the participating GPs will
be included. This is to minimise the potential distress of
asking a patient to change their GP for the purpose of
the study. If there are more than 150 eligible patients, a
simple random sample of 150 of these patients will be
selected. GPs will be asked to review the resulting list to
screen out patients meeting the exclusion criteria. The
practice will send the remaining patients a patient invita-
tion pack including information about the study (see
online supplementary appendix 1), a consent form (see
online supplementary appendix 2) and baseline ques-
tionnaire. Non-respondents will be sent one postal
reminder, supplemented by a telephone reminder when
possible in practices where recruitment targets are not
met.
At sites in England, if a patient lacks capacity to
consent, we will obtain the assent of the patient’s carer,
legal guardian or consultee on behalf of the patient
to take part in the study. Carers will be invited to com-
plete a separate carer contact form, and those who wish
to participate in the carer’s substudy will be sent an
information sheet, consent form and baseline
questionnaire.
Recruitment of patients began on 20 May 2015 and
ended in December 2015. Intervention training began
in June 2015 with intervention delivery period starting
in August 2015 and due to finish in March 2017.
The intervention
Development
The intervention was developed to address the problems
identified in earlier qualitative and quantitative research
on the problems experienced by patients with multimor-
bidity,25–27 along with experience from previous trials
summarised in a systematic review.17 This was followed
by a series of workshops and stakeholder events with
patients, carers, health professionals and health service
managers. This resulted in a complex intervention with
multiple interacting components at the different levels
of individual patient–clinician interactions, practice
organisation, primary–secondary care integration, and
measures to support and incentivise practices to make
changes in their services.
Three general practices participated in an external
pilot and feasibility study in which the feasibility of the
intervention was assessed and improved, and aspects of
trial delivery were tested. The views of the patients and
healthcare professionals delivering the intervention were
fed back to the research team. The key learning points
and changes resulting from the optimisation phase are
described in online supplementary appendix 3.
Intervention components
The name ‘3D’ was chosen because it acts as a mne-
monic for ‘dimensions of health; drugs; depression’ and
also because it alludes to the concept of a holistic, three
dimensional perspective. The main components of the
final 3D intervention, to be tested in the definitive trial,
are illustrated in figure 2 and described below.
The problems experienced by patients with multimor-
bidity in current care were broadly grouped under the
headings of a lack of holistic patient-centred care, high
illness burden and high treatment burden. Strategies
were identified to try to address each of these problems,
as shown in the middle column of figure 2. Finally the
specific operational mechanisms or active components
of the intervention which will be used to implement
each strategy are described in the third column.
Components at practice level relating to organisation of care
The aim is to identify a group of patients with high
levels of multimorbidity and on several QOF disease reg-
isters in order to prioritise them for a different form of
care, recognising that they have more complex needs
than most patients. Consenting patients with multimor-
bidity (as defined in box 1) will be identified and
‘flagged’ on practice computer systems. They will be
allocated a named GP with responsibility for their care
(and nurse if possible, particularly in larger practices
where several nurses are involved in chronic disease
management). These patients will be provided with a
‘3D’ card in order to identify themselves with practice
receptionists when booking appointments. The 3D card
reminds the patient of their named responsible GP, and
encourages them to ask for a longer appointment than
usual when they think they need one. This recognises
that these patients often need to discuss several pro-
blems at one appointment.
In most general practices in the UK, patients with one
of the chronic conditions listed in box 1 are invited for
review of that condition on a regular basis, such as every
6 or 12 months. At these reviews, the GP or nurse follow
computerised disease management templates to collect
relevant data about aspects of disease control and man-
agement. Patients with multimorbidity may be repeat-
edly called for separate reviews of each of their chronic
conditions, often to see different health professionals,
who use different disease management templates which
include a large amount of duplication (eg, most tem-
plates include measurement of blood pressure and
asking about smoking habits). Under the 3D approach,
these separate disease-focused reviews will be replaced
by a 3D review every 6 months at which all problems will
be reviewed at one time.
Components relating to clinicians conduct of reviews
The 3D reviews are comprehensive and, although they
include the important aspects of disease management
included in single disease reviews, they have a different
focus. The conduct of the reviews will be supported by a
bespoke ‘dynamic’ template which automatically perso-
nalises for individual patients to only include prompts
relevant to the conditions that the patient is recorded as
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having in the electronic medical record. It eliminates
the problem of duplication of information between dif-
ferent single disease templates and also provides a struc-
ture to encourage the clinicians to enact the 3D
approach. The term ‘3D’ acts as a mnemonic to encour-
age clinicians to focus on the following:
Dimensions of health: This includes first eliciting
patients’ concerns and priorities for improving their
quality of life and function, before collecting data about
disease metrics such as weight or blood pressure.
Depression: The clinicians should screen for depression
and seek to treat it if identified.
Drugs: In order to address problems of polypharmacy, a
pharmacist will review the patient’s medical records
prior to the 3D review and make recommendations
about low priority drugs that might be discontinued, or
other ways of simplifying drug regimes, for example,
using long-acting medications, so that all tablets can be
taken in the morning. The pharmacist review is per-
formed online through remote access to patients’ elec-
tronic medical records by prior arrangement between
the practice and pharmacist. As part of the 3D review,
the GP will be trained to ask questions to detect pro-
blems with medication adherence and how to help the
patient to address this.
Each six-monthly 3D review consists of two appoint-
ments. At the first appointment (lasting approximately
30–40 min), the practice nurse will collect information
to complete the template and organise all relevant
blood tests or other investigations. The nurse review
includes collecting information about the patient’s prior-
ities for change and aspects of quality of life such as
pain and function, and also includes screening for
depression using the Patient Health Questionnaire 9
(PHQ9) questionnaire.28 Following the nurse appoint-
ment, the patient will be given a document, known as
the ‘3D agenda’, which summarises their assessment and
details their top priorities for change. This will set the
agenda for the second appointment, approximately
1 week later, with the patient’s usual GP. At this 20 min
appointment the GP will review all the information col-
lected by the nurse and from the test results, undertake
a thorough medication review with the help of the phar-
macist’s recommendations, seek to address the patient’s
priorities and problems identified in the assessment,
and agree a written care plan for the patient to take
away. This 3D Health Plan spells out the specific pro-
blems identified (which may be a combination of
patients’ priorities and problems identified by the nurse
or doctor during the review), along with mutually
agreed actions that patients and clinicians each have
responsibility for. Providing patients with a 3D health
plan as a printed summary of their 3D review and test
results is intended to promote patient engagement.
Figure 2 3D logic model. GP, general practitioner; LTC, long term conditions; QOL, quality of life.
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Each general practice will be allocated a designated
‘generalist physician’ (usually a geriatrician) in second-
ary care whom they can contact to discuss individuals
with complex problems and (if possible) to help coord-
inate use of hospital investigations and appointments
where patients are attending numerous different special-
ist clinics or having multiple hospital-based tests on dif-
ferent days.
Components relating to supporting practices
In order to support the implementation of the interven-
tion, the study team developed a training package of two
half-day sessions for healthcare professionals. These ses-
sions are facilitated by a clinician trainer and at least one
local researcher, covering tasks and discussion topics
including eliciting of patient concerns, exploring strat-
egies to promote patient-centred care, ways to improve
continuity of care, negotiating a patient health plan,
improving medication adherence, the aims of the 3D
reviews and use of the 3D review template. A substantial
element of the training will be devoted to promoting
attitudinal change among clinicians towards identifying
and responding to patients’ own priorities and problems
with broader quality of life, as organisational change is
unlikely to be effective unless clinicians ‘buy into’ the
underlying philosophy of the new approach.29 Practice
receptionists will also be offered training in promoting
continuity of care and offering longer appointments to
patients with multimorbidity.
A number of other strategies are being followed to
promote implementation of the intervention within
practices. In addition to the bespoke computerised 3D
review template, we have also developed software to
facilitate identification and monitoring of the partici-
pants. Financial reimbursement is provided to practices
to cover the costs of practice staff training and setting up
of the necessary patient recall systems. Modest financial
incentives (£60 per patient) are also provided to prac-
tices based on the number of patients that complete
both of their six-monthly 3D reviews within the
15-month follow-up period. Each practice will be asked
to nominate a GP champion to help monitor and
promote the intervention within the practice, and also
to meet and share good ideas and experiences with
other GP champions in local collaboratives. The practice
champions will be provided with monthly feedback
reports about their practice’s progress in implementing
the reviews. We will allow local adaptation of the inter-
vention to reflect local context while ensuring the key
elements of the conceptual framework (those shown in
figure 2) are maintained.30
Control group
Patients in practices allocated to the control arm will
continue to receive care as usual. In most practices, this
will mean patients are recalled to different clinics to see
different practice nurses to review each of their long-
term conditions. The nurses will usually follow disease-
specific computerised protocols for their management,
and will mainly focus on collecting data related to QOF
targets rather than quality of life or patients’ priorities.
The nature of ‘care as usual’ may vary between practices
and over time—this will be explored in the process
evaluation.
Participant withdrawal
Among intervention practices, if any participant later
requests not to receive the 3D intervention, they will
revert to the usual care provided for other patients in
their practice. Unless a patient requests to withdraw
from the trial they will continue to be followed up and
will be analysed in the group to which the practice was
allocated. If they wish to withdraw from the trial, then
no further follow-up data will be requested but data
already provided will be used.
Outcome measures
Primary outcome measures
The primary outcome for patient and carers will be
health-related quality of life (HRQoL) as measured by
the EQ-5D-5L after 15 months following patient recruit-
ment.31 The EQ-5D is a widely used self-reported
generic measure of HRQoL which has been validated in
many different patient populations including diabetes,
cardiovascular problems, chronic obstructive pulmonary
disease, cancer, chronic pain and rheumatoid arthritis.
The five-level version (EQ-5D-5L) contains the same
dimensions as the earlier three-level version (EQ-5D-3L)
but has been designed to provide greater reliability and
sensitivity.
Secondary outcomes
Secondary outcome measures for participants are
grouped under domains as shown in box 2.
Secondary outcome measures for carers will assess
measures of carer quality of life and strain, including the
EQ-5D-5L,31 the Carer Experience Scale39 and the Brief
Treatment Burden Questionnaire for carers. These will
be reported separately, as they are not participant
outcomes.
Measures of process of care
We will monitor processes in the intervention practices
in order to report the degree of implementation of the
intervention. This will include the number of nurse and
GP 3D reviews undertaken, the extent to which the 3D
template was fully completed, the number of pharmacy
reviews performed, whether an agenda and health plan
were created and printed off to give to the patient, and
the number of times the hospital general physician was
contacted.
The continuity of care (COC) measure40 will be used
as a measure of longitudinal continuity, for all telephone
or face-to-face consultations by participants with GPs or
nurses within the practice over the 15-month follow-up
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period, adjusted for continuity in the 15 months before
the intervention.
Although also required for the economic analysis, the
number of primary care consultations and the number
of hospital admissions will be of particular interest as
indicators of the effect of the intervention on primary
and secondary health services.
We will report descriptively the systems in place to
provide care for patients with multimorbidity in practices
in both arms of the trial at baseline and at the end of
the 15-month follow-up period, in particular to capture
whether there are differences in ‘usual care’ in the
control arm practices over the period of this study.
Economic evaluation
The economic evaluation will be undertaken from the
perspectives of (1) NHS and personal social services
(PSS) and (2) patients. We will compare the extra cost
of caring for patients in the intervention group with the
difference in outcome as measured by the EQ-5D-5L
and related quality-adjusted life years (QALYs). Resource
use data will be collected from patient self-reported
postal questionnaires at baseline, 9 and 15 months and
GP practice records. The questionnaires will ask about
the use of community and secondary care health ser-
vices, social services, informal care, and personal costs
(including travel, loss of earnings and dependent care
costs). Patients indicating use of hospital services will be
contacted by telephone to obtain more detail about the
inpatient stay or accident and emergency visit. GP prac-
tice records will be used to obtain information about all
available primary care contacts, including type of con-
sultation and who was seen, tests and investigations, and
prescribed medication.
Trial records will be used to estimate the cost of
setting up the 3D service and training staff. This will be
identified and reported separately from the running
costs.
NHS resources will be valued using national published
sources such as Curtis,41 NHS reference costs42 and the
British National Formulary (BNF).43
Data collection
At baseline, data will be collected on the sociodemo-
graphic measures (number of long-term conditions; age;
gender; education; ethnicity; deprivation status (index of
multiple deprivation based on postcode); work status)
and all primary and secondary outcomes. The primary
outcome will be collected 9 and 15 months after recruit-
ment, with the primary outcome time point being at
15 months. All but one of the secondary outcomes will
be collected at 9 months, as shown in box 2. All second-
ary outcomes, measures of the process of care and mea-
sures of resource utilisation will be collected 15 months
after recruitment. Practice randomisation occurs after
patient recruitment, and it then takes approximately
3 months to train practices to deliver the 3D interven-
tion. Patients have their 3D reviews on a six-monthly
cycle. Therefore, collecting outcome data 9 and
15 months after patient recruitment allows for a
3-month lag time and ensures that most patients will be
invited to have two 3D reviews before outcomes are
measured.
The primary method of self-reported data collection
will be via postal questionnaires; however, alternative
completion methods including by telephone or via a
home visit by a researcher masked to treatment alloca-
tion will be offered if necessary in order to maximise
response rates.
Two reminders, the first by letter or email (approxi-
mately 10–14 days after posting the questionnaire) and
the second by phone (approximately 10–14 days after
the first reminder), will be made for participants who
have not returned their questionnaire. Patients will be
given £5 gift vouchers for completion of questionnaires.
No data about identifiable patients will leave the prac-
tice unless patients have provided consent. All data will
be stored securely and confidentially at the University of
Bristol in line with its data management policies.
Sample size
The study is designed to detect an effect size of 0.274
SDs in the primary outcome of the EQ-5D-5L. Data
about the variability of the new five-level (5L) version of
the EQ-5D is currently more limited than for the well-
established three-level (3L) version. The SD of the
EQ-5D-3L in the UK general population is 0.23, rising to
0.27 in the oldest respondents (aged over 75).44 Hence,
an effect size of 0.274 would equate to a detectable
Box 2 Secondary outcomes for patients participating in
the 3D trial
Experience of holistic patient-centred care
▸ Consultation and Relational Empathy (CARE) measure of rela-
tional continuity in general practitioner and nurse*
consulations32
▸ Coordination of care (two questions from LTC6 Quality
Innovation Productivity and Prevention (QIPP) programme)
▸ Patient Assessment of Chronic Illness Care (PACIC) measure33
▸ Overall satisfaction (single item)
Burden of illness measures
▸ Self-rated health
▸ Illness burden in multimorbidity (Bayliss)34
▸ Quality of disease management (a composite measure of
Quality and Outcomes Framework (QOF) achievement)35
▸ Hospital Anxiety Depression Scale (HADS)36
Burden of treatment
▸ Brief Treatment Burden Questionnaire†
▸ Morisky Medication Adherence Scale (eight-item)37
▸ Number of prescribed drugs
▸ Number of high-risk drug combinations38
*Not collected at 9 months follow-up
†New measure developed for this study, based on qualitative
interviews, item generation, principle components analysis and
testing of psychometric properties.
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difference of (0.274×0.27)=0.074 on the EQ-5D-3L, pre-
viously deemed to be the minimum important differ-
ence.45 Although there are less data about the variability
in the 5L version of the EQ-5D than the 3L version, this
latest version is likely to have greater sensitivity to
change.31
Based on data available from our previous studies,1 we
estimated that 2.3% of adult patients would have multi-
morbidity as defined in this study. This equates to about
108 patients in an average-sized practice of 6000
patients. Recruiting 32 practices would therefore provide
3456 potentially eligible patients. Assuming 40% of
patients agree to participate (n=1382), 80% are followed
up to 12 months, and an intraclass correlation coeffi-
cient (ICC) of 0.03 for clustering at the practice level
(based on the WISE trial),46 32 practices will provide
approximately 90% power, with a 5% α level to detect
an effect size of 0.274 SDs in the EQ-5D-5L measure
between the intervention and control groups.
Allocation
General practices will be the unit of allocation. Practices
will be allocated in a 1:1 ratio to receive either the inter-
vention or continue care as usual (control group).
Randomisation will be stratified by area (Bristol, Greater
Manchester, Glasgow) and minimised by deprivation
level and practice size. Within each area allocation will
be performed in blocks of two, with both practices in a
block randomised at the same time and released to the
trial manager together to ensure allocation concealment
and no selection bias. It was not deemed possible to
increase or vary the block sizes given the small number
of practices recruited to each area and the dynamic
nature of recruitment. The trial manager will notify the
local research team of the two allocations and they will
then notify the practices and arrange training of the
intervention practice. The allocation schedule will be
computer-generated by the trial statistician, blind to
details of the practices apart from those needed for
stratification and minimisation.
Randomisation of a practice will take place after
patients in that practice have been identified and invited
to participate in order to avoid selection bias.
Blinding
Once participants have been recruited, it will not be pos-
sible to mask participants or healthcare professionals to
the group allocation of their practice. It is also not feas-
ible to blind all members of the study team actively
involved in the execution of the study. However, data
entry and checks of data quality will be conducted by
administrative staff masked to treatment allocation.
Analysis of outcomes will be performed by the trial statis-
tician, also masked to treatment allocation.
Statistical methods
Data will be analysed in accordance with CONSORT
principles and its extension for cluster randomised
trials. Descriptive statistics will be used to summarise
characteristics of practices and patients and compare
baseline characteristics between groups. A full statistical
analysis plan will be developed and agreed by the Data
Monitoring Committee (DMC) and the Trial Steering
Committee (TSC) after completion of the pilot phase
and prior to undertaking any analyses of the main trial.
All analyses of primary and secondary outcomes will
be at the patient level and will account for clustering by
practice using multilevel regression models. Analyses will
be performed on an ‘as allocated’ basis. Primary analysis
comparing EQ-5D-5L between the intervention and
control practices will employ a linear multilevel regres-
sion model adjusted for stratification/minimisation vari-
ables. Subsequent models will adjust for baseline
EQ-5D-5L, any variables demonstrating imbalance at
baseline and other important prognostic variables such
as age, number of long-term conditions, deprivation and
depression. Preplanned analyses of secondary outcomes
will also employ linear or logistic (as appropriate) multi-
level regression models.
Formal tests of interaction will be performed to con-
sider the following potential effect modifiers: age,
number of chronic conditions, index of deprivation, and
presence or absence of depression alongside physical
health problems. The trial is not specifically powered for
such interaction tests; hence, interpretation will focus on
the CIs and will be hypothesis-generating only. The
potential impact of missing data will be examined
through sensitivity analyses.
Anonymised data will be used in order to compare
descriptive data for consenting versus non-consenting
patients. We will explore the possibility of comparing
QOF performance in patients with chronic conditions
both with and without multimorbidity—this is to assess
for the potential unintended consequence that concen-
trating effort on patients with multimorbidity may have a
positive or negative impact on the care of other patients.
No interim analyses are planned.
Economic analysis
Cost per patient will be estimated by applying unit costs
to the resources used. In a cost-consequences analysis,
we will relate the mean cost per participant in each
group with changes in a range of outcomes; cost-
effectiveness analysis from the NHS and PSS perspective
will estimate the incremental cost per QALY gain where
QALYs are estimated using the EQ-5D-5L. Uncertainty
will be addressed in sensitivity analyses and by using
bootstrapping to estimate the net monetary benefit and
a cost-effectiveness acceptability curve.
Process evaluation
Alongside the main analysis of quantitative outcomes
from the trial, we are conducting a nested process evalu-
ation. This mixed-methods study aims to better under-
stand how and why the intervention was effective or
ineffective and to identify contextually relevant strategies
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for successful implementation as well as practice difficul-
ties in adoption, delivery and maintenance of the inter-
vention. Further details of the protocol for the process
evaluation will be published in a separate paper.47
ETHICS
Ethics approval
This study will be conducted in accordance with princi-
ples of good clinical practice.
Patients will not be denied any form of care that is
currently available in the NHS by participating in this
study. Patients from usual care practices will still have
access to all locally recommended treatments and ser-
vices. Patients from intervention practices will still have
full access to their GP and secondary care services in
addition to their six-monthly 3D assessments. Any
changes in medication prescribing will be performed by
a GP in the context of normal clinical care.
Patient safety
We will monitor and report descriptively the numbers of
serious adverse events in each arm which appeared to
be related to the intervention or the trial, and also the
number of deaths in each trial arm. Given that patients
with multimorbidity may be heavy users of secondary
care services, new medical diagnoses, hospital admis-
sions and deaths are expected and will not be consid-
ered as potential serious adverse events unless anyone
involved in the study (participants, general practice staff
or research staff) notify the research team of any events
that they consider may have been related to the inter-
vention or the research process. All deaths will be inves-
tigated for relatedness by requesting the patient’s GP
provide details of cause of death and relatedness to
study.
Study management and oversight
The 3D Study is managed by the Trial Management
Group, consisting of the chief investigator, principal
investigators and researchers from each of the recruiting
sites and other co-applicants. There is additional govern-
ance oversight by an independent TSC and an inde-
pendent DMC, both constituted in line with guidance
from the National Institute for Health Research
(NIHR). An advisory group with members from key
local and national stakeholder organisations and lay
members has been convened to provide advice about
the wider context, other related initiatives and to facili-
tate communication and eventual knowledge mobilisa-
tion with regard to this trial. There is an active patient
and carer forum which meets regularly to advise on the
design and conduct of the study.
The project will seek to maximise the impact of the
research by adopting a model of knowledge transfer. We
aim to disseminate our findings to patients, healthcare
professionals, commissioners and other academics. In
addition to publication of study results, guides for
commissioners and for practices will be produced to
enable wider implementation of the new 3D approach.
The RCGP Clinical Innovation and Research Centre will
facilitate wide dissemination to practices and the produc-
tion of these resources.
The research team is committed to full publication of
the results. Authorship will be in accordance with the
guidance of the International Committee of Medical
Journal Editors. All authors will have full access to the
study data. Once the main results have been published,
data may be available to other investigators subject to
agreement about the protocol with the chief investigator
and compliance with policies of the funder and sponsor
in relation to data sharing. The study sponsor and the
funder will have no role in study design, data collection,
management, analysis or interpretation of data, writing
of the final report or the decision to submit for
publication.
DISCUSSION
This large and rigorous trial will provide robust evidence
about the benefits and costs of a pragmatic intervention
to improve the management of multimorbidity in
general practice. It builds on a considerable evidence
base about the difficulties experienced by patients with
multimorbidity and the health professionals who seek to
care for them. Through the use of a patient-centred
conceptual framework, it tests a range of strategies
which should address these difficulties and improve out-
comes that matter to patients. The study is highly prag-
matic.48 It is based in a range of normal general practice
settings and in the different health economies of
England and Scotland, which will enhance generalisabil-
ity. It includes patients with broad inclusion criteria and
few exclusion criteria, and assesses a wide range of out-
comes including those relating to health status, patient
experience and resource utilisation. Implementation of
the intervention is flexible to local context, but the
extent to which the intervention adheres to the key-
intended principles will be monitored.
The study is being conducted with considerable atten-
tion to principles of knowledge translation. If the inter-
vention is effective, it will be possible to roll it out
quickly to general practices across the UK, and the 3D
approach is also likely to be applicable to the manage-
ment of patients with multimorbidity in many other
countries.
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